Cara Therapeutics Inc CARA stock spiked 34 percent Wednesday after the company reported that a Phase 2/3 trial for intravenous CR845 met primary and secondary endpoints.
The investor bullishness resonated with Needham.
The Rating
Needham analyst Alan Carr maintained a Buy rating on Cara and raised the price target from $23 to $28.
The Thesis
Although Cara’s high dose met primary endpoints for pain relief, the low dose missed statistical significance. Nonetheless, the analyst regards the profile of the post-surgery pain reliever, including low addictive qualities and low rates of nausea and vomiting, as “attractive.” (See Carr's track record here.)
Carr expects Cara will need to complete another Phase 3 trial in post-surgical pain before securing regulatory approval for the candidate, but the positive Phase 2/3 results are seen to reduce program risk.
Needham predicts the follow-up trial will begin in early 2019 with commercial launch in the second half of 2021. It also anticipates Phase 3 trial results for intravenous CR845 in uremic pruritus — an indication seen to be Cara’s strategic priority — in the first half of 2019.
Price Action
Cara shares were trading up 1 percent at $18.24 at the time of publication Thursday morning.
Related Links:
Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
